

# James P Luyendyk

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8700784/james-p-luyendyk-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

1,338  
citations

22  
h-index

36  
g-index

42  
ext. papers

1,610  
ext. citations

5.3  
avg, IF

4.59  
L-index

#	Paper	IF	Citations
40	Von Willebrand factor exerts hepatoprotective effects in acute but not chronic cholestatic liver injury in mice. <i>Toxicology</i> , <b>2021</b> , 463, 152968	4.4	0
39	Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury. <i>Blood</i> , <b>2021</b> , 137, 2520-2531	2.2	2
38	Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1390-1408	15.4	3
37	Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1264-1265	13.4	2
36	Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 146-155	13.4	15
35	Direct Amplification of Tissue Factor:Factor VIIa Procoagulant Activity by Bile Acids Drives Intrahepatic Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 2038-2048	9.4	7
34	The multifaceted role of fibrinogen in tissue injury and inflammation. <i>Blood</i> , <b>2019</b> , 133, 511-520	2.2	135
33	Plasminogen Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 1204-1212	5.8	4
32	Platelets as Modulators of Liver Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 114-125	5.3	24
31	Von Willebrand factor deficiency reduces liver fibrosis in mice. <i>Toxicology and Applied Pharmacology</i> , <b>2017</b> , 328, 54-59	4.6	13
30	Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis. <i>Toxicology</i> , <b>2017</b> , 377, 73-80	4.4	7
29	Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte $\beta$ 1 integrin-dependent upregulation of Mmp12. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 787-797	13.4	32
28	Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis. <i>Journal of Biochemical and Molecular Toxicology</i> , <b>2017</b> , 31, 1-7	3.4	9
27	Thrombin promotes diet-induced obesity through fibrin-driven inflammation. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 3152-3166	15.9	51
26	Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 397-407	5.3	11
25	Fibrin deposition following bile duct injury limits fibrosis through an $\text{M}\alpha$ -dependent mechanism. <i>Blood</i> , <b>2016</b> , 127, 2751-62	2.2	23
24	Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease. <i>Toxicology</i> , <b>2016</b> , 365, 9-16	4.4	7

23	Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. <i>Blood</i> , <b>2015</b> , 126, 1835-43	2.2	34
22	Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 617-25	13.4	166
21	H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 307, G219-28	5.1	13
20	Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 351, 288-97	4.7	39
19	Hepatocyte tissue factor activates the coagulation cascade in mice. <i>Blood</i> , <b>2013</b> , 121, 1868-74	2.2	50
18	Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 2321-9	5.8	27
17	Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1117-25	5.8	30
16	Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 2278-89	5.8	30
15	Tissue factor contributes to neutrophil CD11b expression in alpha-naphthylisothiocyanate-treated mice. <i>Toxicology and Applied Pharmacology</i> , <b>2011</b> , 250, 256-62	4.6	16
14	Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. <i>Toxicological Sciences</i> , <b>2011</b> , 119, 233-43	4.4	16
13	Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. <i>American Journal of Pathology</i> , <b>2010</b> , 176, 177-86	5.8	38
12	Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 296, G840-9	5.1	34
11	Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. <i>Hepatology</i> , <b>2007</b> , 46, 1177-86	11.2	110
10	Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 322, 852-61	4.7	34
9	Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. <i>Toxicological Sciences</i> , <b>2006</b> , 90, 569-85	4.4	17
8	Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 317, 635-43	4.7	19
7	Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 314, 1023-31	4.7	49
6	Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. <i>Toxicological Sciences</i> , <b>2004</b> , 80, 203-13	4.4	19

5	Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. <i>Hepatology</i> , <b>2004</b> , 40, 1342-51	11.2	44
4	Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 307, 9-16	4.7	122
3	Augmentation of aflatoxin B1 hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. <i>Toxicological Sciences</i> , <b>2003</b> , 72, 171-81	4.4	25
2	Antigen-presenting cell function during <i>Plasmodium yoelii</i> infection. <i>Infection and Immunity</i> , <b>2002</b> , 70, 2941-9	3.7	35
1	Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. <i>Toxicological Sciences</i> , <b>2002</b> , 68, 220-5	4.4	26